Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Emergent BioSolutions Inc.NYSE: EBS

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $88.5M fell 16.3% year over year, ahead of the -38.7% change in trailing-twelve-month cost of revenue. Sequentially, it fell 13.3% from the prior quarter. Over 3 fiscal years it compounded at -15.3% a year.

Context

  • Cost of revenue amounted to 52.8% of revenue in FY2025, down 11.2 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -16.3% holds above the trailing-twelve-month pace of -38.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$88.5M-13.3% QoQ
Last fiscal yearDec 2025
$392.3M-41.3% YoY
LTMMar 2026
$376M-38.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.3%——
1 year-41.3%——
3-year CAGR-15.3%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
392.3M USD
Year-over-year change
-41.3%
4-year CAGR
-20.5%

Cost of Revenue vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -38.7% is the lowest of 7, against a peer median of +11.2%.
  • Cost of revenue amounts to 55.6% of revenue for EBS, versus a peer median of 35.0%.
EBS Competitors
Cost of Revenue for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDLSNDL Inc.LTM Mar 2026CA$682.57M CAD+0.2%+6.3%72.8%
EBSEmergent BioSolutions Inc.LTM Mar 2026$376M USD-38.7%-15.3%55.6%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$151.94M USD+37.2%+9.4%29.6%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$146.39M USD+62.5%+68.6%35.0%
SIGASIGA Technologies, Inc.LTM Mar 2026$32.49M USD+15.1%+41.7%34.6%
PRTAProthena Corporation plcLTM Mar 2026$30.8M USD——53.2%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$19.82M USD-5.8%+123.9%6.6%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$18.37M USD+7.2%-4.0%36.5%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$306K USD———
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$55K USD———
CMPSCOMPASS Pathways plcLTM Mar 2026$0 USD———
Peer median (excluding EBS) —+11.2%+25.6%35.0%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77B1.12B1.05B1.04B742.9M
Cost of Revenue980.4M644.5M689.3M668.2M392.3M
Gross Profit793.2M473M360M375.4M350.6M
Gross Margin44.7%42.3%34.3%36.0%47.2%
Research & Development235.2M188.3M111.4M70.7M53.8M
Selling, General & Admin348.7M339.5M356.7M298.7M186.6M
Operating Expenses451.8M643M1.09B484.1M240.4M
Depreciation & Amortization118.2M125M121.1M105.6M98.3M
EBITDA504.2M15.7M(47M)53.4M240.4M
EBITDA Margin28.4%1.4%-4.5%5.1%32.4%
Operating Income341.4M(170M)(726.4M)(108.7M)110.2M
Operating Margin19.2%-15.2%-69.2%-10.4%14.8%
Interest Income00000
Interest Expense34.5M37.3M87.9M71M59.3M
Other Income / Expenses(38.2M)(49M)(4.8M)(34.2M)(27.4M)
Income Before Tax303.2M(219M)(731.2M)(142.9M)82.8M
Pre-Tax Margin17.1%-19.6%-69.7%-13.7%11.1%
Income Tax Expense83.7M(7.4M)29.3M47.7M30.2M
Net Income219.5M(211.6M)(760.5M)(190.6M)52.6M
Net Margin12.4%-18.9%-72.5%-18.3%7.1%
EPS (Basic)4.10(4.22)(14.85)(3.60)0.98
EPS (Diluted)4.06(4.22)(14.85)(3.60)0.93
Weighted Avg Shares53.5M50.1M51.2M53M53.5M
Weighted Avg Shares (Diluted)54.1M50.1M51.2M53M56.7M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.